They clearly show that c-MYC overexpression in livers of transgenic mice prevented the development of diabetes following streptozotocin (STZ) treatment, not only by inducing hepatic glucose uptake and utilization, but also by blocking gluconeogenesis and ketogenesis [131]. The gene discussed is MYC; the disease is diabetes mellitus.